AFP and neoplasm: Despite sharing the same driver mutation, HBCV-HCC patients had older age at tumor diagnosis (median age, 62.5 vs. 57 years, P = 0.1507), lower tumor grade (grade 3–4 tumors: 25% vs. 45%, P = 0.1594), and lower AFP levels (> = 100 ng/mL: 13% vs. 34%, P = 0.1879) than did HBV-HCC patients (Supplementary Table 3), showing the same trend as in Table 1.